To fully determine the effect of treatment group on Hb change, we used random effects models using the repeat measures at days 30 and 90.
We performed analysis of variance on TCF7 and EOMES with repeated measures at days 0 (pre-transplant), 30, 60 and 100, and we found that both TCF7 and EOMES were significantly higher in the PGE2-UCBT group (P<0.001) compared with the control-UCBT group.
One thousand cells were plated on day one and proliferation rate was measured at days four and six.
Complete blood cell counts were measured at days 1, 8 and 15 of each 21-day cycle.
Immune indices including total coelomocytes count (TCC), phagocytosis, superoxide anion production, superoxide dismutase (SOD) activity and total nitric oxide synthase activity (T-NOS) were measured at days 7, 11, 15, 18, 22, 25 and 29.
SOFA and APACHE II scores as well as serum were measured at days 1,2 and 5.
Troponin, catecholamines, lactates, creatininemia, platelets, fibrinogen, hemoglobin and CRP were measured at days 0, 1, 2, 3, 4, 5, 7 and 10.
C reactive protein levels, measured at days 1 and 2 after inclusion were significantly higher among patients requiring IMV (p = 0.04).
(D J) Cytokine IP-10, TNF-α, MIP-1α, KC, MCP-1, MCP-3 and RANTES levels from virus-infected lungs were measured at days 3, and 5 dpi by ELISA.
Uptake in MC7-L1 ER+ and ERαKD tumor-bearing mice was measured at days 0, 7, and 14 after the start of the treatment (control, n = 5 (a); fulvestrant, n = 4 (b); letrozole, n = 5 (c); tamoxifen, n = 5 (d)).
P24 antigen production was measured at days 4, 8 and 12 of culture supernatant.
